Key result
VERVE-101 is a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol.
Why the study?
Does VERVE-101 permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol?
Does VERVE-101 permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol?
Answers are grounded in this paper and cite their sources.
VERVE-101 is a novel CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and lower LDL-cholesterol.
Just over two decades ago, a new member of the secretory subtilase family, neural apoptosis-regulated convertase 1 (NARC-1), now known as proprotein convertase subtilisin/kexin type 9 (PCSK9), w...
No takes yet. Share an insight, caveat, or question.
Hooper et al. (2024) studied this question. VERVE-101 is a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol.
Synapse has enriched 10 related papers. Consider them for comparative context: